AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32152693 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion with indwelling needles
Number of subjects: 110
Study 32152693 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion with steel needles
Number of subjects: 110
Study 35337021 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir + Ribavirin for 4 weeks
Number of subjects: 27
Study 35337021 — intervention group
Group type: COMPARATOR
Intervention: Glecaprevir/Pibrentasvir for 8 weeks
Number of subjects: 27
Study 35337021 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline viral load <2 mill IU/mL
Number of subjects: 27
Study 36243227 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct consultations with a medical physicist during treatment simulation and before the first treatment.
Number of subjects: 0
Study 36243227 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no direct consultations with a medical physicist).
Number of subjects: 0
Study 36243227 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct consultations with a medical physicist.
Number of subjects: 0
Study 34062000 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic segmentation and quantification of epicardial adipose tissue (EAT) using a multi-slice deep neural network and deformable model.
Number of subjects: 103
Study 34062000 — intervention group
Group type: COMPARATOR
Intervention: Manual delineation by two radiology experts.
Number of subjects: 103
Study 32788139 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text reminders sent two days before appointments and an additional reminder seven days after missed appointments.
Number of subjects: 9368
Study 32788139 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMS reminders).
Number of subjects: 9368
Study 36169959 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate (DMF)
Number of subjects: 150
Study 36169959 — intervention group
Group type: COMPARATOR
Intervention: Interferon β-1a (IFNβ-1a)
Number of subjects: 150
Study 32324840 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic treatment (IHT) with homeopathic remedies at 30C (10-60) and 200C (10-400) dilutions
Number of subjects: 0
Study 32324840 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment
Number of subjects: 0
Study 32324840 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 0
Study 36494544 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification and Referral to Improve Safety (IRIS) intervention adapted for general dental practices
Number of subjects: 0
Study 33662894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate 100 mg once daily
Number of subjects: 397
Study 33662894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate 200 mg once daily
Number of subjects: 397
Study 33662894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate 400 mg once daily
Number of subjects: 397
Study 33662894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study 32040868 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin cream (5%) for 7 days
Number of subjects: 48
Study 32040868 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream for 7 days
Number of subjects: 48
Study 33684953 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 tablet of metformin SR 1000 mg and 1 tablet of TQ 50 mg once daily (T1)
Number of subjects: 60
Study 33684953 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 tablet of metformin SR 1000 mg and 2 tablets of TQ 50 mg once daily (T2)
Number of subjects: 60
Study 33684953 — intervention group
Group type: COMPARATOR
Intervention: 1 tablet of metformin SR 1000 mg only (R)
Number of subjects: 60
Study 33164575 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting with 3-min bouts of simple resistance activities (SRA) every 30 minutes (SRA3)
Number of subjects: 24
Study 33164575 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting with 6-min bouts of simple resistance activities (SRA) every 60 minutes (SRA6)
Number of subjects: 24
Study 33164575 — intervention group
Group type: COMPARATOR
Intervention: Uninterrupted sitting (SIT)
Number of subjects: 24
Study 32248191 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare consumption and costs for women with endometriosis
Number of subjects: 431
Study 32248191 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare consumption and costs for women under 30 years
Number of subjects: 431
Study 32248191 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-related outcomes for women with endometriosis
Number of subjects: 431
Study 34217808 — intervention group
Group type: EXPERIMENTAL
Intervention: CAEP Acute AF/AFL Best Practices Checklist
Number of subjects: 718
Study 34217808 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 718
Study 32027810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low dosage of rituximab (200 mg single infusion)
Number of subjects: 8
Study 36293985 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT + RT
Number of subjects: 18
Study 36293985 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + HIIT
Number of subjects: 18
Study 33370140 — intervention group
Group type: EXPERIMENTAL
Intervention: Supporter help with calling health care providers
Number of subjects: 239
Study 33370140 — intervention group
Group type: EXPERIMENTAL
Intervention: Supporter help with remembering medical appointments
Number of subjects: 239
Study 33370140 — intervention group
Group type: EXPERIMENTAL
Intervention: Supporter help with giving directions when blood sugars were low
Number of subjects: 239
Study 33370140 — intervention group
Group type: COMPARATOR
Intervention: Patient perception of supporter helpfulness
Number of subjects: 239
Study 35945573 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality lactation room
Number of subjects: 328
Study 35945573 — intervention group
Group type: COMPARATOR
Intervention: Low-quality lactation room
Number of subjects: 328
Study 33532037 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) circuit program, 6 stations, 3 days/week for 12 weeks
Number of subjects: 36
Study 33532037 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 36
Study 32847833 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal haemoglobin (HbF) levels
Number of subjects: 452
Study 32847833 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of HbF
Number of subjects: 452
Study 32847833 — intervention group
Group type: EXPERIMENTAL
Intervention: HbF levels in full statistical model
Number of subjects: 452
Study 35333885 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3-fortified fruit juices containing 4000 IU (100 mcg) daily for 8 weeks
Number of subjects: 120
Study 35333885 — intervention group
Group type: COMPARATOR
Intervention: Placebo-fruit juices daily for 8 weeks
Number of subjects: 120
Study 33530982 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 44
Study 33530982 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 44
Study 36288843 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling (DN) intervention, performed thrice a week for 2 weeks, in addition to conventional treatment
Number of subjects: 44
Study 36288843 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment, performed once a day for 40 min, five times a week for 2 weeks
Number of subjects: 44
Study 36288843 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling (DN) intervention
Number of subjects: 44
Study 36288843 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 44
Study 33333459 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support alert for carbohydrate-containing medication orders
Number of subjects: 280
Study 33333459 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support alert
Number of subjects: 280
Study 35435565 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models for predicting postoperative remission at 3 months
Number of subjects: 152
Study 35435565 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models for predicting remission at last visit
Number of subjects: 152
Study 35435565 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models for predicting resistance to somatostatin receptor ligands (SRL)
Number of subjects: 152
Study 34031278 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudendal nerve block anesthesia + stepwise dissection and incisional local anesthesia (Group A)
Number of subjects: 300
Study 34031278 — intervention group
Group type: COMPARATOR
Intervention: Bilateral pudendal nerve block anesthesia (Group B)
Number of subjects: 300
Study 34031278 — intervention group
Group type: COMPARATOR
Intervention: Pudendal nerve block anesthesia + local infiltration anesthesia (Group C)
Number of subjects: 300
Study 32942054 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person method (n = 46)
Number of subjects: 1113
Study 32942054 — intervention group
Group type: COMPARATOR
Intervention: Digital method (n = 92)
Number of subjects: 1113
Study 32942054 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 1113
Study 32942054 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic evaluation
Number of subjects: 1113
Study 34184202 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise training (IET) at 60% of pre‐assessed maximum aerobic power, 3 times per week for 7 months
Number of subjects: 44
Study 34184202 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise training (IET)
Number of subjects: 44
Study 34184202 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no exercise)
Number of subjects: 44
Study 33830998 — intervention group
Group type: EXPERIMENTAL
Intervention: 850 mg metformin three times daily
Number of subjects: 390
Study 33830998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 35750726 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 512
Study 35750726 — intervention group
Group type: EXPERIMENTAL
Intervention: MI aided by the interactive patient communication tool, the Cariogram
Number of subjects: 512
Study 35750726 — intervention group
Group type: COMPARATOR
Intervention: MI (Group II)
Number of subjects: 512
Study 35750726 — intervention group
Group type: COMPARATOR
Intervention: MI aided by the interactive patient communication tool, the Cariogram (Group III)
Number of subjects: 512
Study 35750726 — intervention group
Group type: COMPARATOR
Intervention: Oral health education (Group I)
Number of subjects: 512
Study 33541896 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial spin-labeling MRA
Number of subjects: 29
Study 33541896 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced time-resolved MRA
Number of subjects: 29
Study 33541896 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined arterial spin-labeling MRA and contrast-enhanced time-resolved MRA
Number of subjects: 29
Study 35261289 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 142
Study 35261289 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 142
Study 32965585 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily
Number of subjects: 2055
Study 32965585 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg twice daily
Number of subjects: 2055
Study 32965585 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 1 mg/kg twice daily
Number of subjects: 2055
Study 33612031 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + NS
Number of subjects: 40
Study 33612031 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 40
Study 33612031 — intervention group
Group type: COMPARATOR
Intervention: NS
Number of subjects: 40
Study 33612031 — intervention group
Group type: COMPARATOR
Intervention: RT + placebo
Number of subjects: 40
Study 33612031 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 34845600 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactocare® (two times daily for 12 weeks)
Number of subjects: 64
Study 34845600 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two times daily for 12 weeks)
Number of subjects: 64
Study 34845600 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactocare®
Number of subjects: 64
Study 34845600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 33179818 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump therapy with continuous glucose monitoring offering low glucose suspend (LGS)
Number of subjects: 144
Study 33931361 — intervention group
Group type: EXPERIMENTAL
Intervention: Superselective RAPN (SS-RAPN) with near-infrared fluorescence (NIRF)
Number of subjects: 50
Study 33931361 — intervention group
Group type: COMPARATOR
Intervention: Conventional RAPN with renal artery early unclamping
Number of subjects: 50
Study 33931361 — intervention group
Group type: EXPERIMENTAL
Intervention: Superselective RAPN (SS-RAPN)
Number of subjects: 50
Study 32799429 — intervention group
Group type: COMPARATOR
Intervention: Primary Healthcare (PHC)
Number of subjects: 1386
Study 32799429 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary Healthcare (SHC)
Number of subjects: 1386
Study 32799429 — intervention group
Group type: COMPARATOR
Intervention: PHC
Number of subjects: 1386
Study 32799429 — intervention group
Group type: EXPERIMENTAL
Intervention: SHC
Number of subjects: 1386
Study 32799429 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and diabetes duration
Number of subjects: 1386
Study 32799429 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor glycemic control, hyperlipidemia, hypertension
Number of subjects: 1386
Study 32799429 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity and reduced physical activity
Number of subjects: 1386
Study 34843843 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment with 30 pre- and 10 postoperative exposures at 243 kPa for 90 min each
Number of subjects: 65
Study 34843843 — intervention group
Group type: COMPARATOR
Intervention: Surgical removal of necrotic bone only (Control group)
Number of subjects: 65
Study 34843843 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment
Number of subjects: 65
Study 34843843 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 65
Study 34033889 — intervention group
Group type: EXPERIMENTAL
Intervention: CRPA identified through surveillance cultures (51.4%) and clinical cultures (49.6%)
Number of subjects: 37
Study 34033889 — intervention group
Group type: EXPERIMENTAL
Intervention: Infections in kidney transplant recipients
Number of subjects: 37
Study 34033889 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for CRPA acquisition
Number of subjects: 37
Study 35300657 — intervention group
Group type: EXPERIMENTAL
Intervention: FDI criteria
Number of subjects: 185
Study 35300657 — intervention group
Group type: COMPARATOR
Intervention: CARS criteria
Number of subjects: 185
Study 32920607 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide gel (Opalescence, Ultradent Products) (2 h/day, for 14 days)
Number of subjects: 40
Study 32920607 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% hydrogen peroxide gel (Opalescence Boost, Ultradent Products) (three bleaching sessions, once a week, 45 min/session)
Number of subjects: 40
Study 32920607 — intervention group
Group type: EXPERIMENTAL
Intervention: whitening rinse (Listerine Whitening Extreme, Johnson & Johnson) (2 min/day, for 14 days)
Number of subjects: 40
Study 32920607 — intervention group
Group type: COMPARATOR
Intervention: distilled water (control)
Number of subjects: 40
Study 36331921 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo treatment
Number of subjects: 8
Study 36331921 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 8
Study 33537745 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 9891
Study 33537745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9891
Study 33114392 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 86
Study 33114392 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 86
Study 35461522 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted cH8/1N1-cH5/1N1-cH11/1N1
Number of subjects: 507
Study 35461522 — intervention group
Group type: COMPARATOR
Intervention: IIV4-placebo-IIV4
Number of subjects: 507
Study 35461522 — intervention group
Group type: EXPERIMENTAL
Intervention: non-adjuvanted cH5/1N1-placebo-cH8/1N1
Number of subjects: 507
Study 35461522 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted SUIV
Number of subjects: 507
Study 35461522 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted SUIV
Number of subjects: 507
Study 35461522 — intervention group
Group type: EXPERIMENTAL
Intervention: All chimeric vaccines
Number of subjects: 507
Study 35461522 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 507
Study 34558940 — intervention group
Group type: EXPERIMENTAL
Intervention: randomized measurement settings generated by a discrete group of fermionic Gaussian unitaries, implementable with linear-depth circuits
Number of subjects: 0
Study 34558940 — intervention group
Group type: EXPERIMENTAL
Intervention: randomized measurement settings with particle-number symmetry
Number of subjects: 0
Study 35717987 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy (relugolix 40 mg, estradiol 1 mg, norethisterone acetate 0.5 mg)
Number of subjects: 1261
Study 35717987 — intervention group
Group type: COMPARATOR
Intervention: Relugolix combination therapy
Number of subjects: 1261
Study 32152174 — intervention group
Group type: EXPERIMENTAL
Intervention: cTBS+iTBS
Number of subjects: 36
Study 32152174 — intervention group
Group type: COMPARATOR
Intervention: sham cTBS+iTBS
Number of subjects: 36
Study 32152174 — intervention group
Group type: COMPARATOR
Intervention: sham cTBS+sham iTBS
Number of subjects: 36
Study 36494245 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia (Group D)
Number of subjects: 74
Study 36494245 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anesthesia (Group T)
Number of subjects: 74
Study 36494245 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anesthesia methods (Group T and Group D)
Number of subjects: 74
Study 33549463 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Reported Functional Status (PRFS)
Number of subjects: 13045
Study 33549463 — intervention group
Group type: EXPERIMENTAL
Intervention: Eastern Cooperative Oncology Group (ECOG)
Number of subjects: 13045
Study 33549463 — intervention group
Group type: COMPARATOR
Intervention: Model with PRFS
Number of subjects: 13045
Study 33549463 — intervention group
Group type: COMPARATOR
Intervention: Model with ECOG
Number of subjects: 13045
Study 33549463 — intervention group
Group type: COMPARATOR
Intervention: Model with clinical characteristics only
Number of subjects: 13045
Study 32087032 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bacterial lysate (heat-killed Escherichia coli and Enterococcus faecalis)
Number of subjects: 606
Study 32087032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study 36156542 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine and chondroitin sulfate supplementation for 4 weeks in addition to manual therapy and resistance exercise training.
Number of subjects: 24
Study 36156542 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy and resistance exercise training.
Number of subjects: 24
Study 34444594 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercises + Pain Neuroscience Education (PNE)
Number of subjects: 72
Study 34444594 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercises alone
Number of subjects: 72
Study 34444594 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 32192592 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (first tertile, median = 7.7 MET hours/week)
Number of subjects: 785
Study 32192592 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (second tertile, median = 27.8 MET hours/week)
Number of subjects: 785
Study 32192592 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (third tertile, median = 95.7 MET hours/week)
Number of subjects: 785
Study 32192592 — intervention group
Group type: COMPARATOR
Intervention: No physical activity relation
Number of subjects: 785
Study 36197359 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent training
Number of subjects: 2
Study 36197359 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training
Number of subjects: 2
Study 32936981 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally targeted educational booklet about genetic counseling/genetic testing (GC/GT)
Number of subjects: 52
Study 32936981 — intervention group
Group type: COMPARATOR
Intervention: Fact sheet about breast cancer survivorship (control)
Number of subjects: 52
Study 32681726 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial cycle FET
Number of subjects: 9267
Study 32681726 — intervention group
Group type: COMPARATOR
Intervention: Stimulated cycle FET
Number of subjects: 9267
Study 32681726 — intervention group
Group type: COMPARATOR
Intervention: Natural cycle FET
Number of subjects: 9267
Study 35294860 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal psychodynamic therapy
Number of subjects: 242
Study 35294860 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced cognitive behaviour therapy
Number of subjects: 242
Study 35294860 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised treatment as usual
Number of subjects: 242
Study 35294860 — intervention group
Group type: EXPERIMENTAL
Intervention: Global outcome
Number of subjects: 242
Study 35294860 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI predictors
Number of subjects: 242
Study 32306797 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy: aspirin+prasugrel/ticagrelor+vorapaxar
Number of subjects: 130
Study 32306797 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (drop aspirin): prasugrel/ticagrelor+vorapaxar
Number of subjects: 130